Argenx’s VYVGART Hytrulo prefilled syringe for self-injection has received FDA approval for the treatment of adult patients ...

Already thriving with a successful launch of infused Vyvgart and its subcutaneous follow-on Vyvgart Hytrulo to the tune of $2 ...

After proper training on subcutaneous injection technique, the prefilled syringe may be administered by the patient or caregiver.

Argenx (ARGX) stock rises as the FDA approves Vyvgart Hytrulo developed with Halozyme (HALO) for self-injection, the drug's ...

Argenx reports long-term Vyvgart data showing lasting efficacy in gMG and CIDP, with strong safety and symptom control across ...

Amsterdam, the Netherlands Thursday, April 10, 2025, 18:00 Hrs [IST] ...

The U.S. Food and Drug Administration has approved a prefilled syringe version of Netherlands-based Argenx SE's blockbuster ...

The FDA has approved a subcutaneous self-injectable for adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive and adults with chronic inflammatory ...

Piper Sandler analysts highlighted their top picks for biotechnology for investors amid the rollercoaster seen in the equity ...

Argenx (ARGX) announced that the U.S. Food and Drug Administration approved a new option for patients to self-inject VYVGART Hytrulo with a ...

In a statement, Argenx said that the subcutaneously administered drug is the first “meaningful” new treatment option for the approximately 24,000 people living with CIDP in the US in more than ...